ANTX
HEALTHCAREAN2 Therapeutics Inc
$4.65-0.04 (-0.85%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ANTX Today?
No stock-specific AI insight has been generated for ANTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.00$6.91
$4.65
Fundamentals
Market Cap$167M
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume182K
Avg Volume (10D)—
Shares Outstanding36.0M
ANTX News
19 articles- AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumYahoo Finance·May 7, 2026
- AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung DiseaseYahoo Finance·Mar 31, 2026
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific HighlightsYahoo Finance·Mar 17, 2026
- AN2 Therapeutics Announces $40 Million Private Placement FinancingYahoo Finance·Mar 9, 2026
- AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)Yahoo Finance·Mar 3, 2026
- AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare ConferenceYahoo Finance·Feb 17, 2026
- AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung DiseaseYahoo Finance·Jan 12, 2026
- AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Jan 9, 2026
- Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?Yahoo Finance·Jan 9, 2026
- AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific HighlightsYahoo Finance·Nov 12, 2025
- AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)Yahoo Finance·Nov 10, 2025
- AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx ConferenceYahoo Finance·Nov 6, 2025
- AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific HighlightsYahoo Finance·Aug 12, 2025
- AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas DiseaseYahoo Finance·Aug 12, 2025
- AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas DiseaseYahoo Finance·Jul 23, 2025
- AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of EpetraboroleYahoo Finance·Jun 30, 2025
- Positive Signs As Multiple Insiders Buy AN2 Therapeutics StockYahoo Finance·Jun 28, 2025
- AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria ConferenceYahoo Finance·May 29, 2025
- AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific HighlightsYahoo Finance·May 13, 2025
All 19 articles loaded
Price Data
Open$4.73
Previous Close$4.69
Day High$4.82
Day Low$4.60
52 Week High$6.91
52 Week Low$1.00
52-Week Range
$1.00$6.91
$4.65
Fundamentals
Market Cap$167M
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume182K
Avg Volume (10D)—
Shares Outstanding36.0M
About AN2 Therapeutics Inc
Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—